ResMed
559 hedge funds and large institutions have $15.1B invested in ResMed in 2019 Q4 according to their latest regulatory filings, with 83 funds opening new positions, 201 increasing their positions, 178 reducing their positions, and 40 closing their positions.
108% more first-time investments, than exits
New positions opened: 83 | Existing positions closed: 40
89% more call options, than puts
Call options by funds: $59.4M | Put options by funds: $31.4M
43% more funds holding in top 10
Funds holding in top 10: 7 → 10 (+3)
16% more capital invested
Capital invested by funds: $13.1B → $15.1B (+$2.07B)
13% more repeat investments, than reductions
Existing positions increased: 201 | Existing positions reduced: 178
6% more funds holding
Funds holding: 527 → 559 (+32)
0.55% more ownership
Funds ownership: 67.46% → 68.02% (+0.55%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$37.5M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$29.6M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$22.7M |
| 4 |
WT
Washington Trust
Westerly,
Rhode Island
|
+$22.2M |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
+$22.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$34.8M |
| 2 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$26.7M |
| 3 |
WBC
Westpac Banking Corp
Sydney,
Australia
|
-$17.3M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$17M |
| 5 |
Schroder Investment Management Group
London,
United Kingdom
|
-$16.8M |
RMD Hedge Fund Activity: Q4 2019 in Review
559 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in ResMed (RMD) for Q4 2019, worth a combined $15.1B — up 16% from $13.1B a quarter earlier.
Buyers outnumbered sellers: 83 funds opened new RMD positions and 40 closed out — a net gain of 43 holders — while 201 added to existing stakes and 178 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $37.5M. The largest seller was JP Morgan Chase, cutting an estimated $34.8M.
- 559 institutional investors held ResMed (RMD) as of Q4 2019, up from 527 in Q3 2019.
- Funds reported $15.1B of ResMed stock for Q4 2019, up 16% quarter-over-quarter.
- 83 funds opened new ResMed positions in Q4 2019 and 40 closed out, a net change of +43 holders.
- The largest ResMed buyer in Q4 2019 was Morgan Stanley, an estimated $37.5M added.
- The largest ResMed seller in Q4 2019 was JP Morgan Chase, an estimated $34.8M sold.
Based on aggregated 13F filings for Q4 2019.